Lili Sophie Sester

University of Heidelberg
DISCOVER NUTRIENTS – Understanding the relationship between nutrition and microbiome in MM
View More

Kiyosumi Ochi

Massachusetts General Hospital
A scalable manufacturing platform for externally controllable universal CAR T-cell products
View More

Josefine Krüger

Charité Universitätsmedizin, Berlin, Germany
Investigation of the molecular mechanism of GCK-inhibition as therapeutic approach in multiple myeloma
View More

David Garrido

Hospital de Clínicas Dr. Manuel Quintela
Evaluation of single nucleotide variants in DNA repair and cell cycle control genes in multiple myeloma patients undergoing hematopoietic stem cell transplant and their association with clinical outcomes
View More

Sara Taranto

University of Brescia, Italy
Investigating CREB1 signaling as a novel therapeutic target in multiple myeloma
View More

Florentin Späth

Umeå University, Sweden
Biomarkers for monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma
View More

Andrea Poletti

University of Bologn, Italy
Ancestrality of genomic alterations in Multiple Myeloma: impact on the clonal evolution and on the Minimal Residual Disease dynamics
View More

Smith Giri

University of Alabama Birmingham
Optimizing Melphalan dose among older adults with Multiple Myeloma receiving Autologous Stem Cell Transplantation
View More

David Garrido

Hospital de Clínicas "Dr. Manuel Quintela", Uruguay
Evaluation of single nucleotide polymorphisms of BRCA1, CDKN1A, TP53BP, and XRCC1 in multiple myeloma patients undergoing hematopoietic stem cells transplant and their association with clinical outcomes
View More

Sara Gandfoli

Hematology Research Unit, University of Helsinki, Finland
Investigating the molecular mechanisms of microenvironment-dependent immune escape to natural killer cells in myeloma to uncover biomarkers for rational combination treatment strategie
View More

Lucia Chen

Weatherall Institute of Molecular Medicine, United Kingdom
Immune cell contribution to drug-resistance in Multiple Myeloma
View More

Urvi Shah

Memorial Sloan Kettering
Spatial and temporal tumor genomic heterogeneity in extramedullary multiple myeloma and solitary plasmacytoma with minimal marrow involvement
View More

Teoh Phaik Ju

University of Singapore, Singapore
Systematic functional genomics characterization of 17p13(del) multiple myeloma
View More

Laura Notarfranchi

University of Parma, Italy
Role of flow cytometry and especially its use in the definition of the measurable residual disease (MRD) in multiple myeloma
View More

Elias Mai

Heidelberg University Hospital, Germany
Patterns of relapse from complete response during different maintenance strategies
View More

Sara Gandfoli

Dana-Farber Cancer Institute
Dissecting the mechanisms of Multiple Myeloma (MM) resistance to Natural Killer (NK) cells and the role of NK cells-macrophage interaction in MM immune-evasion
View More

Marc-Andrea Bärtsch

Heidelberg University Hospital, Germany
Deciphering the human plasma cell niche and its transformation in multiple myeloma by highly multiplexed tissue imaging
View More

Jean-Baptiste Alberge

Center for Research in Cancerology and Immunology Nantes-Angers, France
The permissive immune microenvironment is a critical regulator of disease progression from SMM to overt MM, and defining these alterations is critical for the development of translational prognostic and mechanistic models of disease progression
View More

Raphael Szalat

Boston Medical Center
MOLECULAR CHARACTERIZATION AND THERAPEUTIC TARGETING OF PROTEIN KINASE D2 IN T(4;14) MULTIPLE MYELOMA
View More

Julie O'Neal

 Washington University in St. Louis
BCMA-iNKT-CAR for the Treatment of Multiple Myeloma
View More

Paola Neri

University of Calgary, Cumming School of Medicine, Calgary, Canada
Immunogenomics-guided adaptive cellular therapies in Multiple Myeloma
View More

Guido Marcucci

City of Hope
PNC-27: A Novel Effective Strategy for Targeting the Achilles’ Heel of Multiple Myeloma
View More

Why Become a Member

The International Myeloma Society is a professional, scientific, and medical society established to bring together clinical and experimental scientists involved in the study of myeloma. The purpose of this society is to promote research, education, clinical studies (including diagnosis and treatment), workshops, conferences, and symposia on all aspects of multiple myeloma worldwide.

The IMS is a membership organization comprised of basic research scientists, and clinical investigators in the field along with physicians and other healthcare practitioners.

Stay updated on our Events